Liquid Biopsy Segmentation
The global liquid biopsy market is segmented by product type into tools, assay kits & reagents, and services. Amongst these segments, the tools segment is estimated to hold the highest share of 66% in 2021. The tools segment is further estimated to achieve a revenue of USD 2481.3 Million in 2021 and further garner 66.20% share by the end of 2036. Further, the market is segmented by samples into blood, urine, and others, out of which, the blood segment is expected to hold a significant market share throughout the forecast period, as the liquid biopsy process is usually conducted using blood samples. The market is further segmented by end user into hospitals, clinics, research laboratories, academic institutes, and others. Out of these, the hospitals segment is projected to gain the largest share of around 41% during the forecast period. Based on disease indication, the market is segmented into lung, colorectal, breast, prostate, liver, and head & neck cancers, and others. Out of these, the breast cancer segment is estimated to garner the highest market revenue by the end of 2028, owing to the growing incidence of breast cancer among women has led to many challenges for its treatment on account of its complexity in nature. The breast cancer segment is estimated to attain revenue of USD 908.3 Million in 2021 and further garner USD 6703.1 Million in 2028.
